These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37715566)

  • 1. Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis.
    Kang N; Fan B; Sun Y; Xue P; Liu Y
    Cancer Sci; 2023 Nov; 114(11):4413-4425. PubMed ID: 37715566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial-Specific Molecule 1 Inhibition Lessens Productive Angiogenesis and Tumor Metastasis to Overcome Bevacizumab Resistance.
    Kang N; Liang X; Fan B; Zhao C; Shen B; Ji X; Liu Y
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New medications; bevacizumab].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
    Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
    Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
    Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
    Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in the treatment of colorectal cancer.
    Cilley JC; Barfi K; Benson AB; Mulcahy MF
    Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
    Pavlidis ET; Pavlidis TE
    World J Gastroenterol; 2013 Aug; 19(31):5051-60. PubMed ID: 23964138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
    Kong DH; Kim MR; Jang JH; Na HJ; Lee S
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting angiogenesis in esophagogastric adenocarcinoma.
    Okines AF; Reynolds AR; Cunningham D
    Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).
    Zinser-Sierra JW; Rodríguez-Ramírez S; Villalobos-Valencia R; Ramírez-Márquez M
    Drugs R D; 2011; 11(2):101-11. PubMed ID: 21679003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
    O'Connor JP; Carano RA; Clamp AR; Ross J; Ho CC; Jackson A; Parker GJ; Rose CJ; Peale FV; Friesenhahn M; Mitchell CL; Watson Y; Roberts C; Hope L; Cheung S; Reslan HB; Go MA; Pacheco GJ; Wu X; Cao TC; Ross S; Buonaccorsi GA; Davies K; Hasan J; Thornton P; del Puerto O; Ferrara N; van Bruggen N; Jayson GC
    Clin Cancer Res; 2009 Nov; 15(21):6674-82. PubMed ID: 19861458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.
    Varol U; Yildiz I; Salman T; Karabulut B; Uslu R
    Tumori; 2014; 100(4):370-6. PubMed ID: 25296585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
    Fernando NH; Hurwitz HI
    Oncologist; 2004; 9 Suppl 1():11-8. PubMed ID: 15178811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.